



Implementation Model for *in vitro* Diagnostic Medical Devices Regulation Step by Step Guide

MEDICAL DEVICES CHANGE OF LEGISLATION What you need to know!



| | STEP | INTENTION / ACTION |
|---|---|--|
| | Pre-assessment | Brief management to ensure a clear understanding of the importance and business implications of the IVDR |
| | | Consider organisational challenges: management awareness, staffing capability and availability, budget implications |
| | Gap analysis and actions resulting from this | Assess impact on products, internal resources, organisation and budget |
| | | Check new classification rules (IVDR Classes A–D) and confirm conformity assessment routes for existing and future products. Check the requirement for involving the Notified Bodies |
| | | Review the changes needed to existing technical documentation (Technical Files) |
| | | Review and upgrade quality management system (QMS) (point 3 below) |
| 2 | | Check the adequacy of available clinical evidence and risk management and identify any gaps (Article 56) |
| | | Review product labelling (Annex I Chapter III) |
| | | Ensure post-market surveillance (PMS) arrangements are adequate (Chapter VII Section 1) |
| | | Prepare a post-market performance follow-up plan (PMPF, Annex XIII Part B) |
| | | Get ready for the new vigilance requirements (Chapter VII Section 2) |
| | | Ensure the respect of traceability obligations (Chapter III) |
| | Quality Management System (QMS) | Review adequacy of QMS to meet standards and processes for IVDs under the new Regulation |
| 3 | | Build new regulatory requirements into the QMS |
| | | Identify/hire the person responsible for regulatory compliance within your organisation (Article 15) and be sure it is adequately qualified and trained |

Internal market, Industry, Entrepreneurship and SMEs

| | Clarify how the company is affected: legal entities, obligation of economic operators, organisational structures and resources |
|---------------------------------------|---|
| 4 Legal entities | Consider organisational challenges: management awareness, staffing capability and availability, budget implications |
| | Ensure product liability insurance is adequate |
| 5 Portfolio | Do a cost/benefit analysis for your product portfolio; bear in mind costs related to the new risk classification system and the need of involving a Notified Body and costs for post-market surveillance and gaps in the technical documentation, and plan your transition to the IVDR accordingly |
| - | Review supply chain provisions, and clarify roles and responsibilities of business partners (authorised representatives, importers, distributors) |
| 6 Master implementation | Build a roadmap for implementation, including definition of sub-projects, resource requirements and a steering group, and ensure overall responsibility for IVDR implementation has been established |
| D plan | Give special consideration to certificate expiry dates, bearing in mind the transitional period, transitional provisions and availability of your Notified Bodies |
| 7 Notified Bodies | Contact the selected Notified Bodies and determine their capacity and availability to service the implementation plan |
| 8 Regulatory training | Empower and train staff through IVDR implementation and transition workshops |
| | Implement the various sub-projects (performance evaluation, technical documentation, relations with other economic operators, Unique Device Identification, labelling, post-market surveillance, vigilance, and reporting IT systems) |
| Execute master implementation plan | Ensure a cross-functional project management team is in place to cover all aspects of implementation |
| | Ensure overall and individual responsibilities for IVDR implementation have been established |
| Review efficiency and | Implement regular meetings on project status and progress, discrepancy and gap analyses, risks, next steps and requirements |
| effectiveness | Hold regular progress reviews against the IVDR implementation plan and include thes in the management review process |
| 1 Notified Body submission | Discuss submission dates to avoid delays in the approval process |
| | Actively monitor the still-developing European regulatory environment and guidelines expected in the coming months (check DG GROW web pages on medical devices and subscribe to the newsletter) |
| 12 Ongoing monitoring | Establish a procedure for dealing with unannounced inspections from Notified Bodies |
| | Regularly review the IVDR implementation plan, identifying and addressing key areas of risk |

20/11/2018

© European Union, [2018] Reuse is authorised provided the source is acknowledged. The reuse policy of European Commission documents is regulated by Decision 2011/833/EU (OJ L 330, 14.12.2011, p. 39).

Funded under the Third EU Health Programme



https://ec.europa.eu/growth/ sectors/medical-devices_en